Navigation Links
Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Date:6/3/2008

percent; no patient achieved an objective response. The median PFS was 2.3 months. Three patients had a >6 month PFS. The disease control and median PFS are similar to results achieved in this patient population for approved agents (panitumumab or cetuximab monotherapy).

Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies.

"The efficacy results in this study are very encouraging, particularly compared to historical data," said Arthur Louie, M.D., chief medical officer of Celator. "These data support that drug ratios may play an important role when combining drugs to treat patients. This study shows that well established drugs with proven activity may offer greater clinical benefit when a synergistic ratio is identified and the individual drugs are locked into a drug delivery vehicle able to deliver and maintain the desired ratio in patients. Our goal is to substantially improve clinical outcomes by using our proprietary CombiPlex(TM) technology."

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach that identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle and maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorect
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
2. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
11. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Over 100 million adults suffer from chronic ... pain daily. Chronic and acute pain dramatically impacts quality ... to fulfill the need for non-surgical, interventional solutions and ... On October 28th, a new pain management center ... community.  This new facility boasts cutting edge ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
Breaking Medicine Technology:New Pain Management Center Opens in Cumberland, Md. 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4
... GRONINGEN, Netherlands , July 26 ... organization providing testing services to support preclinical and clinical ... of Xendo Drug Development BV (XDD), headquartered in Groningen, ... organization (CRO), will be known as QPS Netherlands BV ...
... Harco Metal Products (Harco), an industry leader in tube ... contract to manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products ... risk and cost associated with staff injuries caused by physically lifting ...
Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
(Date:11/27/2014)... 2014 Today, Digital-Signage-China.com adds 2 new items ... a digital signage media player promotion for Dec. 2014. ... a shopping wave in April, and this promotion will help ... find her desired models on our website, she/he can contact ... , The new models come in the latest designs, and ...
(Date:11/27/2014)... November 28, 2014 This is a ... the global Bronchoscopes industry with a focus on the ... market status of the Bronchoscopes manufacturers and is a ... individuals interested in the industry. , Firstly, the report ... definition, applications and manufacturing technology. Then, the report explores ...
(Date:11/27/2014)... Turks and Caicos Islands; BWI (PRWEB) November 28, 2014 ... for the Tuscany Resort in the Turks & Caicos. ... resorts by TripAdvisor in Providenciales, is announcing a few ... three bedroom villa rentals. And they are offering ... resort. , Additionally, The Tuscany, is having a ...
(Date:11/27/2014)... Let the Black Friday sales begin at Sublime ... top, filled with skincare goodies, will delight and please her ... quantities last - no coupon required. See the ... on Amazon at the same sales prices. Links to the ... for ease. , The company published a 2014 Gift ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
Breaking Medicine News(10 mins):Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Big Christmas Sales Begin Today at Sublime Beauty® for all Christmas Gift Selections and Skincare Sets 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2
... educational literature can influence young women,s use of indoor tanning, ... changing their attitudes about indoor tanning and promoting healthier alternatives ... 1, 2008 issue of CANCER , a peer-reviewed journal ... are more than 1.3 million skin cancer diagnoses in the ...
... Hydrate and Soothe Young Throats, FARMINGDALE, N.Y., ... approaches, Integrated Beverage Group, Ltd. (IBG), a manufacturer,of ... newest,product -- Children,s Throat Cooler(R). This non-medicated ready-to-freeze,liquid ... wish to choose a 100%,drug free product to ...
... Access to Care in Underserved,Communities, SAN DIEGO, ... medical care to underserved residents of San Diego ... 17) the,expansion of its telemedicine program, thanks to ... been used to purchase new equipment including a ...
... pressure condition can pose serious threat to woman and ... Pregnant with her second child, Joan didn,t make much ... worsened. By the time she saw her doctor, her ... triggering an emergency Caesarean section. , Joan is ...
... Oklahoma Academy of Ophthalmology hosts event October 24 ... OKLAHOMA CITY, Oct. 17 Oklahoma Academy ... benefiting the,Juvenile Diabetes Research Foundation (JDRF) Central Oklahoma ... Sullivan will headline the,event. Lorena and Gary Story ...
... Well today announced that CEO,Roy Schoenberg, MD, MPH; ... vice president of marketing and communications at Blue,Cross ... live, public,demonstration of Online Care, which is going ... "Deep Dive Demonstration" will take place at 10:00,a.m. ...
Cached Medicine News:Health News:Educational materials can alter young women's attitudes about tanning, may reduce skin cancer 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 3Health News:La Maestra Community Health Centers Expands Telemedicine Program 2Health News:La Maestra Community Health Centers Expands Telemedicine Program 3Health News:Research May Help Predict Preeclampsia 2Health News:Research May Help Predict Preeclampsia 3Health News:Research May Help Predict Preeclampsia 4Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 3Health News:American Well Systems CEO Roy Schoenberg to Present Live Public Demo of First Online Care Service at Health 2.0 Conference 2
Our products, with carefully researched design features, are tailored to making arthroscopic and ligament reconstructive surgery more reproducible, easier, quicker and safer....
... Interference Screws. Optimal screw ... graft selection options. Robust ... deformation, and chamfered screw ... atraumatic tissue fixation. Features ...
Cannulated Interference Screws...
... a low molecular weight that ... viscosity you need to achieve ... small-incision surgery. The sustained viscoelastic ... depth for safe, ample working ...
Medicine Products: